Dynavax's adjuvant for BE's Covid vaccine
Biological E Limited, a Hyderabad-based vaccine and pharmaceutical company, has announced the execution of a commercial supply agreement of Dynavax’s CpG 1018TM advanced adjuvant, for use in its subunit Covid-19 vaccine candidate, Corbevax.
Mahima Datla
Hyderabad: Biological E Limited, a Hyderabad-based vaccine and pharmaceutical company, has announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in its subunit Covid-19 vaccine candidate, Corbevax. Dynavax Technologies Corporation, a biopharmaceutical company, is focused on developing and commercialising novel vaccines.
The commercial supply agreement extends through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax. Pending conditional regulatory approvals in India, BE expects to commence product launch of Corbevax later this year.
"We are pleased to collaborate with Dynavax and our collaboration will produce yet another vital vaccine against the spread of Covid-19. We believe Corbevax will play a critical role in eradicating the global pandemic," said Mahima Datla, Managing Director, Biological E. Limited. Ryan Spencer, Chief Executive Officer of Dynavax said, "Dynavax is proud to extend our collaboration with Biological E with a commercial supply agreement and deliver significant amounts of CpG 1018 in hopes that Corbevax will be an important Covid-19 vaccine protecting people globally regardless of income level."
